Published in Horm Metab Res on August 01, 2001
Estrogen Receptor-β Up-Regulates IGF1R Expression and Activity to Inhibit Apoptosis and Increase Growth of Medulloblastoma. Endocrinology (2015) 2.03
Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends Pharmacol Sci (2010) 1.82
27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol (2007) 1.75
Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression. Exp Gerontol (2013) 1.57
Potential mechanisms of estrogen quinone carcinogenesis. Chem Res Toxicol (2007) 1.56
Redox cycling of catechol estrogens generating apurinic/apyrimidinic sites and 8-oxo-deoxyguanosine via reactive oxygen species differentiates equine and human estrogens. Chem Res Toxicol (2010) 1.07
The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor α-mediated signaling in cancer cells and in cardiomyocytes. PLoS One (2011) 1.01
Estrogen Receptor {alpha} Enhances the Rate of Oxidative DNA Damage by Targeting an Equine Estrogen Catechol Metabolite to the Nucleus. J Biol Chem (2009) 0.99
Weight, dietary behavior, and physical activity in childhood and adolescence: implications for adult cancer risk. Obes Facts (2009) 0.99
Identification of a transcriptional fingerprint of estrogen exposure in rainbow trout liver. Toxicol Sci (2007) 0.96
Blockade of estrogen receptor signaling inhibits growth and migration of medulloblastoma. Endocrinology (2008) 0.90
Current perspectives between metabolic syndrome and cancer. Oncotarget (2016) 0.84
Efficient synthesis, liquid chromatography purification, and tandem mass spectrometric characterization of estrogen-modified DNA bases. Chem Res Toxicol (2008) 0.83
Body size in relation to urinary estrogens and estrogen metabolites (EM) among premenopausal women during the luteal phase. Horm Cancer (2012) 0.81
Menopausal hormone therapy and lung cancer-specific mortality following diagnosis: the California Teachers Study. PLoS One (2014) 0.80
Balance of beneficial and deleterious health effects of quinones: a case study of the chemical properties of genistein and estrone quinones. J Am Chem Soc (2009) 0.78
Alcohol drinking and mammary cancer: Pathogenesis and potential dietary preventive alternatives. World J Clin Oncol (2014) 0.78
Dietary Fat and Fiber Intakes Are Not Associated with Patterns of Urinary Estrogen Metabolites in Premenopausal Women. J Nutr (2015) 0.75
Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med (2000) 2.69
Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene (2006) 2.05
Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med (Berl) (1997) 1.77
Patients' attitudes to totally implantable venous access port systems for gynecological or breast malignancies. Eur J Surg Oncol (2006) 1.61
Fetal adrenal haemorrhage--two-dimensional and three-dimensional imaging. Fetal Diagn Ther (2007) 1.57
Transplacental exposure of neonates to perfluorooctanesulfonate and perfluorooctanoate: a pilot study. Int Arch Occup Environ Health (2007) 1.50
The era of centers: the influence of establishing specialized centers on patients' choice of hospital. Arch Gynecol Obstet (2010) 1.43
Clonal culture of fetal cells from maternal blood. Lancet (2000) 1.41
Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am J Pathol (1999) 1.41
[Sebaceous breast carcinoma: report of a rare histological special subtype]. Pathologe (2014) 1.39
Factors correlating with reexcision after breast-conserving therapy. Eur J Surg Oncol (2008) 1.37
Inhibition of estrogen receptor action by the orphan receptor SHP (short heterodimer partner). Mol Endocrinol (1998) 1.27
Isolation and characterization of the regulatory HEX2 gene necessary for glucose repression in yeast. Mol Gen Genet (1987) 1.22
Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol (1996) 1.15
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer (2012) 1.13
Patterns of allelic loss on chromosome 17 in sporadic breast carcinomas detected by fluorescent-labeled microsatellite analysis. Genes Chromosomes Cancer (1997) 1.13
Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer. J Cancer Res Clin Oncol (2008) 1.13
Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Br J Cancer (1996) 1.13
Defining CD95 as a tumor suppressor gene. J Mol Med (Berl) (2000) 1.13
Risk reducing mastectomy: outcomes in 10 European centres. J Med Genet (2008) 1.12
Ribosomal subunit kinase-2 is required for growth factor-stimulated transcription of the c-Fos gene. Proc Natl Acad Sci U S A (2000) 1.12
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. Br J Cancer (2012) 1.12
Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. Eur J Endocrinol (2004) 1.09
Awareness of breast cancer incidence and risk factors among healthy women. Eur J Cancer Prev (2004) 1.08
Gene amplification and expression of the steroid receptor coactivator SRC3 (AIB1) in sporadic breast and endometrial carcinomas. Horm Metab Res (2001) 1.06
The concept of the certification system of the German Cancer Society and its impact on gynecological cancer care. Arch Gynecol Obstet (2013) 1.05
Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers. J Surg Oncol (2007) 1.03
Frequent allele loss on 9p21-22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer. Genes Chromosomes Cancer (1996) 1.02
Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1. Gynecol Oncol (1995) 1.02
Association of complementary methods with quality of life and life satisfaction in patients with gynecologic and breast malignancies. Support Care Cancer (2007) 1.01
ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues. Int J Cancer (1995) 1.00
Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol (2007) 1.00
[HPV-associated alterations of the vulva and vagina. Morphology and molecular pathology]. Pathologe (2011) 1.00
Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol (2010) 0.99
Fertility preservation in cancer patients. Minerva Ginecol (2010) 0.98
Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors. Cancer Detect Prev (1995) 0.97
Expression of the hyaluronan receptor RHAMM in endometrial carcinomas suggests a role in tumour progression and metastasis. J Cancer Res Clin Oncol (2003) 0.97
FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. Br J Cancer (2014) 0.96
Correlations between anti-müllerian hormone, inhibin B, and activin A in follicular fluid in IVF/ICSI patients for assessing the maturation and developmental potential of oocytes. Eur J Med Res (2007) 0.94
Association of blood group A with early-onset ovarian hyperstimulation syndrome. Transfus Clin Biol (2008) 0.94
Thyroid-stimulating hormone is associated with insulin resistance independently of body mass index and age in women with polycystic ovary syndrome. Hum Reprod (2009) 0.94
Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer (1996) 0.94
DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder. Lab Invest (2000) 0.93
Assessment of breast cancer tumor size depends on method, histopathology and tumor size itself*. Breast Cancer Res Treat (2005) 0.92
[Inflammation of the myocardium as an arrhythmia trigger]. Z Kardiol (2000) 0.92
Differentiation between phyllodes tumor and fibroadenoma using real-time elastography. Ultraschall Med (2011) 0.91
Growth inhibition of xenotransplanted human carcinomas by a monoclonal antibody directed against the epidermal growth factor receptor. Eur J Cancer (1994) 0.90
Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL. Brain Pathol (1998) 0.90
Frequency and quantity of the parvovirus B19 genome in endomyocardial biopsies from patients with suspected myocarditis or idiopathic left ventricular dysfunction. Z Kardiol (2004) 0.90
CDKN2A gene inactivation in epithelial sporadic ovarian cancer. Br J Cancer (1999) 0.89
Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. J Cancer Res Clin Oncol (2008) 0.89
Molecular mechanism of estrogen receptor (ER)alpha-specific, estradiol-dependent expression of the progesterone receptor (PR) B-isoform. J Steroid Biochem Mol Biol (2004) 0.89
Psychosomatic aspects of urinary incontinence. Arch Gynecol Obstet (1999) 0.88
Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diabetes (2005) 0.88
DNA sequence variations of the entire anti-Mullerian hormone (AMH) gene promoter and AMH protein expression in patients with the Mayer-Rokitanski-Kuster-Hauser syndrome. Hum Reprod (2004) 0.88
Endogenous retroviral syncytin: compilation of experimental research on syncytin and its possible role in normal and disturbed human placentogenesis. Mol Hum Reprod (2004) 0.88
Loss of heterozygosity at 11q23.1 and survival in breast cancer: results of a large European study. Breast Cancer Somatic Genetics Consortium. Genes Chromosomes Cancer (1999) 0.87
Comparison of xenografting in SCID mice and LIVE/DEAD assay as a predictor of the developmental potential of cryopreserved ovarian tissue. In Vivo (2006) 0.87
Trans-placental exposure of neonates to acrylamide--a pilot study. Int Arch Occup Environ Health (2004) 0.87
Is it necessary to measure free testosterone to assess hyperandrogenemia in women? The role of calculated free and bioavailable testosterone. Exp Clin Endocrinol Diabetes (2006) 0.86
CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology (2000) 0.86
Prognostic significance of the detection of human papilloma virus L1 protein in smears of mild to moderate cervical intraepithelial lesions. Eur J Obstet Gynecol Reprod Biol (2008) 0.86
Differences in gene expression dependent on sampling site in placental tissue of fetuses with intrauterine growth restriction. Placenta (2010) 0.85
Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates. Oncology (2001) 0.85
Acute promyelocytic leukemia and pregnancy. Eur J Haematol (2000) 0.84
Psychosomatic aspects of vulvodynia. Comparison with the chronic pelvic pain syndrome. J Reprod Med (1999) 0.84
Accuracy of radiological tumour size assessment and the risk for re-excision in a cohort of primary breast cancer patients. Eur J Surg Oncol (2011) 0.83
Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer. Eur J Cancer Prev (2000) 0.83
CD95 ligand expression in dedifferentiated breast cancer. J Pathol (1999) 0.83
Influence of body mass index on measured and calculated androgen parameters in adult women with Hirsutism and PCOS. Exp Clin Endocrinol Diabetes (2007) 0.83
Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin. Int J Cancer (1999) 0.83
Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4. Gynecol Oncol (2006) 0.83
Neoadjuvant chemotherapy in breast cancer: which diagnostic procedures can be used? Anticancer Res (2005) 0.82
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). Br J Cancer (2009) 0.82
The association of prenatal attachment and perinatal factors with pre- and postpartum depression in first-time mothers. Arch Gynecol Obstet (2012) 0.82
Modulation of uterine contractility and peristalsis by oxytocin in estrogen-primed non-pregnant swine uteri. Eur J Med Res (2006) 0.82
Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC). Gynecol Oncol (1994) 0.82
The effect of metformin treatment for 2 years without caloric restriction on endocrine and metabolic parameters in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes (2009) 0.81
Expression analyses of epidermal growth factor receptor and HER-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients. Oncology (1997) 0.81
Mild hydronephrosis after uncomplicated hysterectomy. Eur J Obstet Gynecol Reprod Biol (2013) 0.81
Detection of oestrogen receptors (ER) alpha and beta in conjunctiva, lacrimal gland, and tarsal plates. Eye (Lond) (2004) 0.81
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. Br J Cancer (2011) 0.81
Management and course of histologically verified cervical carcinoma in situ during pregnancy. Acta Obstet Gynecol Scand (2006) 0.81
Herpes gestationis may present itself as a paraneoplastic syndrome of choriocarcinoma-a case report. Gynecol Oncol (2003) 0.81
H-ras gene amplification or mutation is not common in human primary breast cancer. Oncol Rep (1999) 0.81